Analysts Offer Predictions for Heron Therapeutics Inc’s FY2020 Earnings (HRTX)

Heron Therapeutics Inc (NASDAQ:HRTX) – Jefferies Group upped their FY2020 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst B. Amin now forecasts that the biotechnology company will earn $0.75 per share for the year, up from their prior forecast of $0.49. Jefferies Group also issued estimates for Heron Therapeutics’ FY2021 earnings at $2.30 EPS and FY2022 earnings at $3.05 EPS.

How to Become a New Pot Stock Millionaire

A number of other brokerages have also recently commented on HRTX. Cantor Fitzgerald set a $40.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Monday, March 19th. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday. Mizuho restated a “buy” rating and set a $35.00 target price (up previously from $28.00) on shares of Heron Therapeutics in a report on Monday, March 19th. Cowen restated a “buy” rating on shares of Heron Therapeutics in a report on Monday, March 19th. Finally, Needham & Company LLC boosted their target price on shares of Heron Therapeutics to $42.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.00.

Shares of Heron Therapeutics stock opened at $28.20 on Thursday. Heron Therapeutics has a fifty-two week low of $12.70 and a fifty-two week high of $32.70. The company has a market cap of $1,768.13, a price-to-earnings ratio of -7.70 and a beta of 1.87.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The company had revenue of $10.05 million during the quarter, compared to the consensus estimate of $9.00 million.

In other news, VP Kimberly Manhard sold 18,000 shares of Heron Therapeutics stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $30.00, for a total value of $540,000.00. Following the completion of the transaction, the vice president now owns 18,000 shares of the company’s stock, valued at approximately $540,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Barry D. Quart sold 100,000 shares of Heron Therapeutics stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $29.75, for a total value of $2,975,000.00. Following the completion of the transaction, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at approximately $4,997,791.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 225,584 shares of company stock valued at $6,141,680. 19.93% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Parametric Portfolio Associates LLC raised its position in shares of Heron Therapeutics by 2.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 771 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Heron Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 397,456 shares of the biotechnology company’s stock worth $7,193,000 after purchasing an additional 2,410 shares during the last quarter. Fox Run Management L.L.C. raised its position in shares of Heron Therapeutics by 27.5% in the 4th quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 4,750 shares during the last quarter. Jane Street Group LLC raised its position in shares of Heron Therapeutics by 36.3% in the 4th quarter. Jane Street Group LLC now owns 18,806 shares of the biotechnology company’s stock worth $340,000 after purchasing an additional 5,006 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Heron Therapeutics by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 8,135 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3294650/analysts-offer-predictions-for-heron-therapeutics-incs-fy2020-earnings-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Eaton Co.  Expected to Announce Earnings of $1.06 Per Share
Eaton Co. Expected to Announce Earnings of $1.06 Per Share
Micro Focus  Earning Somewhat Favorable Press Coverage, Study Finds
Micro Focus Earning Somewhat Favorable Press Coverage, Study Finds
Randgold Resources  Given Daily News Impact Rating of 0.11
Randgold Resources Given Daily News Impact Rating of 0.11
Camden Property Trust  Getting Positive News Coverage, Report Finds
Camden Property Trust Getting Positive News Coverage, Report Finds
Zacks: Brokerages Expect Spark Therapeutics  Will Announce Quarterly Sales of $53.82 Million
Zacks: Brokerages Expect Spark Therapeutics Will Announce Quarterly Sales of $53.82 Million
USDe  Price Hits $0.0002 on Exchanges
USDe Price Hits $0.0002 on Exchanges


© 2006-2018 Ticker Report. Google+.